Intuniv (Guanfacine)

Guanfacine selectively activates alpha-2A adrenergic receptors in the brain, reducing sympathetic nerve activity and enhancing prefrontal cortex function, which helps control attention and impulse regulation while also causing vasodilation to lower blood pressure.

The appropriate dose of Intuniv is determined by the prescribing clinician based on the patient’s age, condition, and response to therapy. Dosage adjustments are made according to clinical guidelines.

Safety data for guanfacine in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against risks and consider alternative treatments when possible.

To request Intuniv, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Intuniv (guanfacine) is a non‑stimulant that targets alpha‑2A receptors, offering an alternative for patients who cannot tolerate stimulants or need adjunct therapy. Its mechanism differs from dopamine‑reuptake inhibitors, providing a distinct side‑effect profile.

Intuniv tablets should be stored at room temperature, below 25 °C, in the original packaging, protected from moisture and light to maintain stability.

Intuniv is taken orally as an extended‑release tablet, usually once daily in the morning or as directed by a healthcare professional.

Serious risks include severe hypotension, bradycardia, syncope, depression, suicidal thoughts, and rare allergic reactions. Patients should be monitored for these events, especially during dose changes.

Intuniv is contraindicated in patients with known hypersensitivity to guanfacine or any tablet components, and should be used with caution in individuals with severe cardiac conduction disorders, low blood pressure, or hepatic impairment.